Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVENUE THERAPEUTICS, INC.ATXI · Entity 8537 | Director | December 02, 2024 | December 03, 2024 |
| Journey Medical CorpDERM · Entity 6273 | Director | July 01, 2026 | July 02, 2026 |
| MUSTANG BIO, INC.MBIO · Entity 8350 | Director | December 30, 2025 | December 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVENUE THERAPEUTICS, INC.
Report date December 02, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | Direct | 97 |
Reported balance
After 2024-12-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-12-02 · Sale · Disposed 23 · Balance 97 F1: Effective April 26, 2024, the Issuer effected a one-for-seventy-five reverse stock split of its common stock (the "Reverse Stock Split") and the amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective April 26, 2024, the Issuer effected a one-for-seventy-five reverse stock split of its common stock (the "Reverse Stock Split") and the amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.
Journey Medical Corp
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 168,618 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 50,000 · Balance 168,618 F1: On July 1, 2026, the reporting person was granted 50,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030 and 16,667 shares on July 1, 2031. F2: Includes restricted stock units, which vest over various time periods. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 1, 2026, the reporting person was granted 50,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030 and 16,667 shares on July 1, 2031.
F2: Includes restricted stock units, which vest over various time periods.
MUSTANG BIO, INC.
Report date December 30, 2025 · Filed December 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | Direct | 145 |
Reported balance
After 2025-12-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-30 · Sale · Disposed 247 · Balance 145 F1: Represents a private sale of 247 shares of common stock to another member of the board of directors of the Issuer. F2: Effective January 15, 2025, the Issuer effected a one-for-fifty reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a private sale of 247 shares of common stock to another member of the board of directors of the Issuer.
F2: Effective January 15, 2025, the Issuer effected a one-for-fifty reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Checkpoint Therapeutics, Inc.
Report date May 28, 2025 · Filed May 30, 2025
Section 16 reporting ended · disclosed 2025-05-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 147,007 |
Reported balance
After 2025-05-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 12,195 · Balance 147,007 F1: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Herskotitz's continued service on the board. |
| COMMON STOCKSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-05-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-05-30 · Other · Disposed 147,007 · Balance 0 F2: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Herskotitz's continued service on the board.
F2: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency.
NATIONAL HOLDINGS CORP
Report date February 12, 2018 · Filed March 06, 2019
Section 16 reporting ended · disclosed 2019-03-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,593 |
Ending reported balance
After 2019-02-13 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2019-02-12 · Exercise / conversion · Acquired 25,000 · Balance 25,000 F1: Each restricted stock unit converted into one share of National Holdings Corporation (the "Company") common stock. Row 2 · 2019-02-12 · Exercise / conversion · Acquired 3,495 · Balance 28,495 F1: Each restricted stock unit converted into one share of National Holdings Corporation (the "Company") common stock. Row 3 · 2019-02-13 · Exercise / conversion · Acquired 25,000 · Balance 53,495 F1: Each restricted stock unit converted into one share of National Holdings Corporation (the "Company") common stock. Row 4 · 2019-02-13 · Exercise / conversion · Acquired 7,098 · Balance 60,593 F1: Each restricted stock unit converted into one share of National Holdings Corporation (the "Company") common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 50,000 |
Reported balance
After 2018-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-02-12 · Grant · Acquired 50,000 · Balance 50,000 F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3: The restricted stock units vest in two equal annual installments beginning February 12, 2019. Vested shares will be delivered to the reporting person annually in accordance to the vesting delivery schedule. The Company's Board of Directors approved accelerated vesting of the remaining shares on February 13, 2019. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 60,593 |
Reported balance
After 2018-02-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-02-12 · Grant · Acquired 10,593 · Balance 60,593 F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4: The restricted stock units vest in three equal annual installments beginning February 12, 2019. Vested shares will be delivered to the reporting person annually in accordance to the vesting delivery schedule. The Company's Board of Directors approved accelerated vesting of the remaining shares on February 13, 2019. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 35,593 |
Reported balance
After 2019-02-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-02-12 · Exercise / conversion · Disposed 25,000 · Balance 35,593 F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5: On February 12, 2018, the reporting person was granted 50,000 restricted stock units. These stock units vest in two equal annual installments beginning February 12, 2019. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 32,098 |
Reported balance
After 2019-02-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-02-12 · Exercise / conversion · Disposed 3,495 · Balance 32,098 F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6: On February 12, 2018, the reporting person was granted 10,593 restricted stock units. These stock units vest in three equal annual installments beginning February 12, 2019. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,098 |
Reported balance
After 2019-02-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-02-13 · Exercise / conversion · Disposed 25,000 · Balance 7,098 F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F7: On February 12, 2018, the reporting person was granted 50,000 restricted stock units. The Company's Board of Directors approved accelerated vesting of the remaining shares on February 13, 2019. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-02-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-02-13 · Exercise / conversion · Disposed 7,098 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F8: On February 12, 2018, the reporting person was granted 10,593 restricted stock units. The Company's Board of Directors approved accelerated vesting of the remaining shares on February 13, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit converted into one share of National Holdings Corporation (the "Company") common stock.
F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
F3: The restricted stock units vest in two equal annual installments beginning February 12, 2019. Vested shares will be delivered to the reporting person annually in accordance to the vesting delivery schedule. The Company's Board of Directors approved accelerated vesting of the remaining shares on February 13, 2019.
F4: The restricted stock units vest in three equal annual installments beginning February 12, 2019. Vested shares will be delivered to the reporting person annually in accordance to the vesting delivery schedule. The Company's Board of Directors approved accelerated vesting of the remaining shares on February 13, 2019.
F5: On February 12, 2018, the reporting person was granted 50,000 restricted stock units. These stock units vest in two equal annual installments beginning February 12, 2019.
F6: On February 12, 2018, the reporting person was granted 10,593 restricted stock units. These stock units vest in three equal annual installments beginning February 12, 2019.
F7: On February 12, 2018, the reporting person was granted 50,000 restricted stock units. The Company's Board of Directors approved accelerated vesting of the remaining shares on February 13, 2019.
F8: On February 12, 2018, the reporting person was granted 10,593 restricted stock units. The Company's Board of Directors approved accelerated vesting of the remaining shares on February 13, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2019 Filed Feb 6, 2019 21:31 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 7,000 | $5.91 | $41,370.00 |
DisclosureSEC source: 0001144204-19-005339 · tv512626_form4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,813 F1 · price: Reflects the weighted average purchase price of multiple same-day open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on February 4, 2019 was $5.90 to $5.97. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 64,663 shares of restricted stock. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 17:48 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 650 | $5.91 | $3,841.50 |
DisclosureSEC source: 0001144204-19-004355 · tv512263_form4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,813 F1 · balance_after: Includes 64,663 shares of restricted stock. Read SEC document |
| January 29, 2019 Filed Jan 30, 2019 21:18 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 8,553 | $5.91 | $50,548.23 |
DisclosureSEC source: 0001144204-19-003774 · tv512042_form4.xml · nonDerivative · entry 2 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,163 F1 · price: Reflects the weighted average purchase price of multiple same-day open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on January 28, 2019 was $5.82 to $5.89 and the range of prices for the purchase transactions on January 29, 2019 was $5.86 to $5.99. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 64,663 shares of restricted stock. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 21:18 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 1,447 | $5.84 | $8,450.48 |
DisclosureSEC source: 0001144204-19-003774 · tv512042_form4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,610 F1 · price: Reflects the weighted average purchase price of multiple same-day open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on January 28, 2019 was $5.82 to $5.89 and the range of prices for the purchase transactions on January 29, 2019 was $5.86 to $5.99. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 64,663 shares of restricted stock. Read SEC document |
| November 23, 2018 Filed Dec 7, 2018 21:44 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCOMMON STOCK | 1,000 | $3.96 | $3,960.00 |
DisclosureSEC source: 0001144204-18-063619 · tv507723_form4.xml · nonDerivative · entry 2 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 F1 · balance_after: 70,000 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 01:45 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GiftCommon Stock | 14,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-042958 · tv500468_form4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,163 F1 · shares: The 14,663 shares of restricted common stock will vest on August 7, 2021. F2 · balance_after: Includes 64,663 shares of restricted stock. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 21:25 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 16,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-034457 · tv496608_form4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,448 F1 · shares: The 16,448 shares of restricted Common Stock will vest on June 14, 2021, subject to Mr. Herskowitz's continued service on the board on such date. F2 · balance_after: Represents shares of restricted Common Stock which vest over various time periods. Read SEC document |
| June 14, 2018 Filed Dec 7, 2018 21:44 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-063619 · tv507723_form4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · balance_after: 70,000 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| April 25, 2018 Filed Apr 25, 2018 20:30 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 1,000 | $3.80 | $3,800.00 |
DisclosureSEC source: 0001144204-18-022402 · tv492043_form4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 F1 · balance_after: Includes 50,000 shares of restricted stock. Read SEC document |
| February 12, 2018 Filed Mar 6, 2019 19:47 UTC | NATIONAL HOLDINGS CORP NHLD · Entity 142239 | GrantRestricted Stock Units · Derivative | 10,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-004251 · rdgdoc.xml · derivative · entry 6 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,593 Underlying: Common Stock · 10,593 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning February 12, 2019. Vested shares will be delivered to the reporting person annually in accordance to the vesting delivery schedule. The Company's Board of Directors approved accelerated vesting of the remaining shares on February 13, 2019. F4 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning February 12, 2019. Vested shares will be delivered to the reporting person annually in accordance to the vesting delivery schedule. The Company's Board of Directors approved accelerated vesting of the remaining shares on February 13, 2019. Read SEC document |
| February 12, 2018 Filed Mar 6, 2019 19:47 UTC | NATIONAL HOLDINGS CORP NHLD · Entity 142239 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-004251 · rdgdoc.xml · derivative · entry 5 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The restricted stock units vest in two equal annual installments beginning February 12, 2019. Vested shares will be delivered to the reporting person annually in accordance to the vesting delivery schedule. The Company's Board of Directors approved accelerated vesting of the remaining shares on February 13, 2019. F3 · derivative.expiration_date: The restricted stock units vest in two equal annual installments beginning February 12, 2019. Vested shares will be delivered to the reporting person annually in accordance to the vesting delivery schedule. The Company's Board of Directors approved accelerated vesting of the remaining shares on February 13, 2019. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 16:19 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 1,000 | $5.01 | $5,010.00 |
DisclosureSEC source: 0001144204-17-052957 · tv477192_4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,500 F1 · balance_after: Includes 50,000 shares of restricted stock. Read SEC document |
| October 09, 2017 Filed Oct 10, 2017 12:27 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 500 | $5.24 | $2,620.00 |
DisclosureSEC source: 0001144204-17-051782 · tv476706_4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,500 F1 · balance_after: Includes 10,000 shares of restricted stock. Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 21:17 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-032762 · v469072_form4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · shares: The 10,000 shares of restricted Common Stock will vest on June 15, 2020. F2 · balance_after: Represents shares of restricted Common Stock which vest over various time periods. Read SEC document |
| January 13, 2017 Filed Jan 19, 2017 21:35 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK (RESTRICTED) | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-002930 · v457182_form4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: The shares of restricted stock vest as follows: One-third on January 13, 2020, one-third on January 13, 2021 and one-third on January 13, 2022. F1 · balance_after: The shares of restricted stock vest as follows: One-third on January 13, 2020, one-third on January 13, 2021 and one-third on January 13, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.